Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib

Author's Avatar
Jan 25, 2022

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced it has entered into a term loan agreement with Oxford Finance, LLC that is designed to primarily support the commercial preparation and potential launch of momelotinib, an investigational agent for the treatment of myelofibrosis, a rare form of blood cancer. The Company estimates it had cash and cash equivalents of $104.7 million as of December 31, 2021.